Trial Profile
Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2013
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 23 May 2012 Status changed from active, no longer recruiting to completed.
- 23 May 2012 Status changed from active, no longer recruiting to completed.
- 09 Oct 2008 Actual patient number changed from 56 to 53 as reported by ClinicalTrials.gov.